UrexBiotech Report issue

For profit Phase 1
Founded: London ON Canada (1988)
Status: Acquired by Chr Hansen (2009) → now Novonesis (2023)

Organization Overview

First Clinical Trial
2007
NCT00479947
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 1 Trials (2)

lactobacillus reuteri (1 trial)

lactobacillus rhamnosus (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Candidiasis (Phase 1)

Candidiasis, Vulvovaginal (Phase 1)

Vaginitis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2